Multivariate results showed that AFP (HR, 0.330; 95% CI:0.160-0.683; p= 0.003), adjuvant therapy (HR, 0.394; 95% CI: 0.253-0.614; p< 0.001), multiple tumors (HR, 2.011; 95% CI: 1.005-4.022; p = 0.048), MVI (HR, 4.129; 95% CI: 2.008-8.489; p < 0.001), PVTT (HR, 2.436; 95%CI: 1.287-4.611; p= 0.006) and TACE (HR, 0.359; 95% CI: 0.226-0.571; p< 0.001) was a significant factor associated with DFS in HCC patients with high-risk recurrence factors (Table 3). The gene discussed is AFP; the disease is hepatocellular carcinoma.